Verona Pharma (VRNA) Presents At American Thoracic Society International Conference - Slideshow

RPL554 (dual PDE3/4 enzyme inhibitor): Baseline airway reversibility impacts immediate bronchodilation, in contrast to progressive symptom improvement Dave Singh1, Brian T. Maurer,2 Fernando Martinez,3 Thomas Bengtsson4 1. Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 2. Verona Pharma, plc, New York, USA; 3. Weill Cornell Medical College, New York, USA; 4. StatMind AB, Lund, Sweden Introduction Figure 1: Peak FEV1 0–3 h ensifentrine–placebo ...